Asarina Pharma

About Us

Asarina Pharma Asarina Pharma is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Our product pipeline is built on over 40 years of research, and with our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions from Tourette syndrome to OCD..

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Asarina Pharma AB (publ) Interim Report Q2 2020 released

Wed, Aug 19, 2020 08:00 CET

Asarina Pharma CEO Peter Nordkild: “The second Quarter 2020 has given us continued proof of the urgent need for new, safe and effective treatments for the devastating conditions that our flagship compound, Sepranolone, targets. Despite disappointing results in our Phase IIb PMDD study at the beginning of the Quarter, which we covered extensively in our Q1 Interim Report, this second Quarter powerfully underlined the unmet need for new, safe, effective treatments for menstrual migraine and Tourette Syndrome.”FINANCIAL HIGHLIGHTS · Decrease in R&D costs after completion of PMDD study ·

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Asarina Pharma AB (publ) Interim Report Q2 2020 released

Subscribe